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From January to April 2012, 16 cases of W135 invasive 
meningococcal infection were reported in France. Of 
these, eight were linked to a recent travel history to 
Sub-Saharan Africa. These cases were reported in 
France concomitantly with the meningitis epidemic 
season in Sub-Saharan Africa. Considering the high 
number of travellers between France and West-African 
countries belonging to the so-called meningitis belt, 
the French recommendations for travellers stress the 
importance of vaccination before travelling to these 
countries.
In mid-February 2012, two W135 invasive meningococ-
cal disease (IMD) cases were reported in two French 
regions (Pays de la Loire and Rhône-Alpes) in persons 
having recently returned from Senegal. The first case 
had arrived in France on 12 February and was hospi-
talised three days later. The second case arrived on 
19 February and was hospitalised on the same day. 
No connection could be established between the two 
cases but they had both visited the same region in 
Senegal (near Mbour) and they were both working with 
non-governmental organisations (NGOs). 
In France, the annual mean incidence of IMD varies 
between 0.9 and 1.5 cases per 100,000 population. 
Cases are mainly due to serogroup B and C meningo-
cocci (65% and 27% respectively for the last 10 years). 
Serogroup W135 is rare in France; sporadic cases were 
reported in the 1990s (less than five cases per year) 
and they mainly belonged to the clonal complexes 
ST-11 and ST-22 (French National Reference Centre for 
Meningococci (NRCM), unpublished data). However, 
this serogroup underwent a clonal expansion in France 
and other European countries in 2000, during the first 
reported multinational outbreak of serogroup W135 
Neisseria meningitidis infections belonging to a par-
ticular clone of the ST-11 clonal complex. This outbreak 
started among pilgrims to Mecca and their contacts 
[1] and then affected Sub-Saharan countries (mainly 
Burkina Faso) [2,3]. Following a peak of incidence in 
2002 with 42 reported cases, the incidence of W135 
(ST-11) IMD cases decreased in France and the W135 
cases were most frequently due to isolates belonging 
to the clonal complex ST-22 representing in 2011 less 
than 3% of the cases with known serogroup (14/542) 
(NRCM, unpublished data).
Investigation of W135 
meningitis cases in 2012
In 2012, the epidemic meningitis season, which coin-
cides annually with the dry season between December 
and June, had already started in the so-called men-
ingitis belt when the two W135 cases imported from 
Senegal were notified. Therefore we collected informa-
tion regarding recent travel for all the W135 IMD cases 
that occurred in France since the beginning of the year. 
Between 1 January and 1 April 2012, a total number of 
16 IMD cases were notified in France. This is an impor-
tant increase if compared to the previous five years 
when only four to eight W135 cases were reported each 
year during the first five months. 
All 16 cases reported this year were laboratory-con-
firmed through isolation of N. meningitidis, posi-
tive PCR or detection of N. meningitidis antigens. The 
median age of cases was 45 years (range: 2 months 
to 89 years) and the M:F ratio was 9:7. None of the 16 
cases had been vaccinated with a tetravalent A/C/Y/ 
W135 meningococcal polysaccharide vaccine.
For eight of the 16 cases, a link to Sub-Saharan Africa 
was identified: two had returned from Senegal in 
February, one had arrived from Mali four days before 
the disease onset and one arrived from Senegal 15 days 
before the disease onset. The other four cases did not 
travel during their incubation period but a recent travel 
history was found for their close contacts: to Benin for 
one case, to Mali for two cases and to Senegal for one 
case with dates of return to France within the three 
weeks before the disease onset of the case. The pur-
pose of travel was visiting friends and relatives for six 
cases or contacts and working for NGOs for two.
Considering an incubation period of 10 days, the dates 
of arrival in France and onset of the disease, three of 
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the eight cases could be considered as imported. The 
remaining five cases may have been infected by asymp-
tomatic contacts carrying an imported strain. However, 
strains were not investigated among contacts.
Among the eight cases, four cases presented with 
meningitis, two with pneumonia and septicaemia, one 
with arthritis, and one with pericarditis. No death was 
registered among the cases. 
As of 24 May 2012, no other W135 IMD case has been 
notified since 1 April 2012. 
All eight ’possibly import-related’ W135 IMD cases were 
caused by the same strain, characterised at the NRCM 
in Paris by multilocus sequence typing, PorA variable 
regions (VR1 and VR2), penA and fetA genes. The anti-
genic formula was W135:2a:P1-5,2, the genetic typing 
showed porA VR1=5, VR2=2, fetA=F1-1, penA=1, and 
the strains were ST-11. 
Conclusions
The increase of serogroup W135 meningococcal dis-
ease incidence in France in early 2012 was concomi-
tant to the meningitis epidemic season in Sub-Saharan 
Africa. From 1 January to 15 April 2012, almost 15,000 
meningitis cases have been reported in West Africa 
to the World Health Organization. In some countries 
(e.g. Burkina Faso, Côte d’Ivoire, Ghana, Mali, Niger) 
the serogroup W135 was predominant among cases 
for which N. meningitidis has been identified whereas 
serogroup A was predominant in other countries like 
Chad [4]. Serogroup W135 has increased in Niger in 
2010 [5]. No laboratory results were available from 
Senegal. 
The French NRCM typed eight isolates from Côte 
d’Ivoire. These bacteria were isolated in February 
2012 in three different districts of the country. All 
the isolates from France and Côte d’Ivoire shared the 
same tested markers (porA VR1=5, VR2=2, fetA=F1-1, 
penA=1, ST-11) (unpublished data). Eight other cases 
of W135 cases were also isolated in France during the 
same period but they reported no travel history dur-
ing the previous three months. All these isolates also 
showed different markers (unpublished data).
Further investigations are required including typing 
isolates from other countries within the meningitis 
belt and comparing results with isolates from the pre-
vious years in order to help understanding this recent 
re-emergence of W135/ST-11 isolates. A long-lasting 
establishment of this serogroup in sub-Saharan African 
countries may prompt re-considering the vaccination 
strategies in the belt upon the introduction of the con-
jugate vaccine against serogroup A [6].
In the meantime, specific surveillance should be 
enhanced in Europe and recommendations for travellers 
who have contacts with population in high-incidence 
countries should be updated taking into account that 
non-pilgrimage-related travel is rarely associated with 
transmission and that the purposes of travel described 
above for the cases themselves or their asymptomatic 
contacts were visits to family members and friends or 
work for NGOs [7]. Since there are frequent travellers 
between France and West-African countries belonging 
to the meningitis belt, the French recommendations for 
travellers insist on the importance of vaccination with 
a quadrivalent A/C/Y/ W135 vaccine (preferably a con-
jugate vaccine) when travelling to these countries [8].
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